Company / R&D per Share
TG Therapeutics, Inc. R&D per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D per Share
$1.03
FY2025
5-year range
$0.52 / $1.58
FY2021-FY2025
Trend
+65.1%
vs FY2024
Sector context
#145 of 208
Health Care
What the data says
At $1.03, TG Therapeutics, Inc.'s r&d per share ranks #145 of 208 in the Health Care sector. R&D per Share has fluctuated over the past 10 years, ranging from $0.52 in FY2023 to $2.18 in FY2018.
Based on SEC 10-K filings.
1.03 in FY2025 with a 5-year CAGR of -7.5%.
Improved from $0.52 to $1.03 over the past 2 years.
Health Care sector context is included.
R&D per Share over time
Growth rates
- 3-Year CAGR
- +5.5%
- 5-Year CAGR
- -7.5%
- 10-Year CAGR
- -
Sector benchmark
#145 of 208 in Health CareTop 70% of 208This company $1.03 Sector average $28.82
▼
-96.4% below sector average
Key checks
Key Insights
- In FY2025, r&d per share increased 65.1% year-over-year.
- Ranks #145 out of 208 companies in the Health Care sector.
- Peak r&d per share was recorded in FY2018.
- Lowest r&d per share in the period was in FY2023.
Company context
Key Data Points
- Altman Z-Score 1.05 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.03 | +65.1% |
| FY2024 | $0.62 | +19.6% |
| FY2023 | $0.52 | -40.5% |
| FY2022 | $0.88 | -44.7% |
| FY2021 | $1.58 | +4.4% |
| FY2020 | $1.52 | +24.1% |
| FY2019 | $1.22 | -43.9% |
| FY2018 | $2.18 | +31.9% |
| FY2017 | $1.65 | +17.0% |
| FY2016 | $1.41 | +35.1% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026